## Edgar Filing: SACHS BRUCE I - Form 4

GACHE DDUCE I

Form 4	JCEI											
May 16, 201	3											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE OF							NCF C	OMMISSION	OMB APPROVAL			
Check thi		ashington, D.C. 20549				011111551010	OMB Number:	3235-0287				
if no long		STATEMENT OF CHANGES IN BENEFICIAL OWNERSH							Expires:	January 31, 2005		
subject to STATEMENT OF C. Section 16. Form 4 or				SECUR	RITIES				Estimated a burden hour response	•		
Form 5 obligation may cont <i>See</i> Instru 1(b).	ns Section 1	7(a) of the	Public U	tility Hol		ipany	Act of	e Act of 1934, 1935 or Section 0	1			
(Print or Type F	Responses)											
			2. Issuer Name <b>and</b> Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First)				-			_X_Director10% Owner				
			3. Date of Earliest Transaction (Month/Day/Year) 05/14/2013					Officer (give below)		r (specify		
ST.												
			endment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
CAMBRIDO	GE, MA 02139	)						Form filed by M Person	ore than One Re	porting		
(City)	(State)	(Zip)	Tabl	Table I - Non-Derivative Securities Acquired, Disposed of, or Ber					, or Beneficial	y Owned		
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea		n Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit or(A) or Dia (Instr. 3, 4) Amount	sposed	of (D) 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	05/14/2013			S	60,000	D	\$ 81.15 (1) (2)	112,910	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: SACHS BRUCE I - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying rities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
SACHS BRUCE I C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE, MA 02139							
Signatures							
Kenneth L. Horton, Attorney-In-Fact	05/16/2013						
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Open market sales reported on this line occurred at a weighted average price of \$81.15 (range \$80.81 to \$81.41).
- (2) Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.